Information Provided By:
Fly News Breaks for September 30, 2019
MRK, BLU
Sep 30, 2019 | 08:22 EDT
As previously reported, Guggenheim analyst Dana Flanders initiated Bellus Health (BLU) with a Buy rating and $12 price target. BLU-5937 for refractory chronic cough is the primary value driver in "a potential multi-billion dollar category," said Flanders, who also sees the opportunity for label expansion and the potential for M&A interest in Bellus. Merck (MRK) acquired Afferent, which also has a P2X3 antagonist asset called gefapixant, in 2016 for $500M upfront and up to $1.25B with milestones, noted Flanders.
News For BLU;MRK From the Last 2 Days
MRK
Oct 15, 2021 | 12:03 EDT
Shares of Codexis (CDXS) are under pressure after the company revealed that a $29M purchase order from an undisclosed global pharmaceutical customer is for the use of a Codexis enzyme in the manufacture of Pfizer's (PFE) clinical-stage COVID antiviral candidate, not for Merck's (MRK) molnupiravir drug. The stock had... To see the rest of the story go to thefly.com. See Story Here
MRK
Oct 15, 2021 | 07:23 EDT
Merck (MRK) and Eisai (ESALY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted opinions recommending approval of the combination of Keytruda, Merck's anti-PD-1 therapy, plus Lenvima in the European Union for the treatment of advanced renal cell carcinoma, or RCC, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications. One opinion is for the first-line treatment of adult patients with advanced RCC, and the other is for the treatment of adult patients with advanced or recurrent endometrial carcinoma, or EC, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation. Decisions on the CHMP's recommendations will be given by the European Commission for marketing authorization in the EU, and are expected in Q4. If approved, this would be the first combination of an anti-PD-1 therapy with a tyrosine kinase inhibitor approved for the treatment of two different types of cancer in the EU.